RCS - Frontier IP Group - inSignals Neurotech receives EUR100,000 investment

Frontier IPAnnouncement

11/03/2021 07:05

RNS Number : 8470R
  
Frontier IP Group plc
  
11 March 2021
  
 

REACH - non-regulatory announcement 
AIM: FIPP
11 March 2021
 
Frontier IP Group Plc
("Frontier IP" or the "Group")
 
 
 
Portfolio news - inSignals Neurotech receives €100,000 investment from 
Portugal Ventures 
 
 
Frontier IP, a specialist in commercialising intellectual property ("IP"), today announces that portfolio company inSignals Neurotech ("inSignals" or "the Company") has received a €100,000 investment from leading Portuguese venture capital firm Portugal Ventures through its initiative Call INNOV-ID. 
 
The funding will be used by inSignals to accelerate the validation and development of its patented technology to aid deep brain stimulation surgery on patients suffering Parkinson's disease. It will also support validation of other applications in neurology.
 
In particular, it will allow the Company to expand preliminary clinical trials, strengthen its intellectual property position and grow its team. The Company was selected as a 'one to watch' in the Nature Spinoff Prize 2020 and has already received interest from potential industry partners.  It is entering collaboration agreements to extend multi-centre clinical studies in Portugal, the Netherlands, Germany and Spain. 
 
Frontier IP holds a 33 per cent equity stake in inSignals. The Company, a spin out from the Portuguese Institute for Systems and Computer Engineering, Technology and Science ("INESC TEC") with the support of São João University Hospital, part of the University of Porto, is developing wireless wearable devices to precisely measure wrist rigidity to help surgeons place brain implants more accurately to achieve the best clinical results. 
 
Call INNOV-ID is focused on investing in science and technology projects or companies in pre-seed, seed or early stage where the technology is still at a prototype, proof of concept or product market fit validation stage. It was launched in response to a request from the Portuguese government to support technology companies through the COVID-19 pandemic. It is managed by Portugal Ventures, a specialist in seed and early-stage investment in companies operating in digital, engineering and manufacturing, life sciences and tourism, in partnership with ANI, the Portuguese National Innovation Agency, financing specialist PME Investimentos and StartUp Portugal. 
 
InSignals' first product is aimed at Parkinson's disease, and has already undergone three clinical studies involving 59 patients. Increased muscle rigidity is one of the key symptoms of the disease and is often treated by implanting deep brain stimulation electrodes when drugs no longer have an effect. InSignals' devices have shown they could help neurologists and neurosurgeons assess rigidity more objectively and place implants more accurately.
 
Doctors evaluate wrist rigidity during surgery to decide the optimum position for an implant. In some hospitals, two trained surgeons are required to make a judgement by manually manipulating the patient's wrist. This means evaluation can be biased by the physicians' experience and perception. It can also pose difficulties for younger specialists being trained in the procedure. 
 
Other systems designed to provide objective and quantitative evaluation are complicated to set up and are impractical for use during surgical procedures. InSignals' device is easy to set up and use and is currently the only one providing real-time measurements. 
 
Potential applications include helping pharmaceutical companies monitor or assess the impact of new or approved drugs in rigidity reduction during clinical trials. 
 
InSignals was established to commercialise the work of João Paulo Cunha, Associate Professor with Habilitation at the Department of Electrical and Computer Engineering at the Faculty of Engineering of the University of Porto and senior researcher at the INESC TEC Institute for Systems and Computer Engineering. There, he created the Biomedical Research And INnovation (BRAIN) research group and co-founded the Centre for Biomedical Engineering Research. 
 
InSignals Neurotech co-Founder João Paulo Cunha, PhD said: "There is a gap in the objective analysis of neurological motor symptoms. The progress undergone by the inSignals' team assessing rigidity during DBS is attracting much interest in the field.  This funding from Portugal Ventures will expand the clinical studies taking place with some of the most experienced neurologists in Europe. It is also a starting point to leverage international funds to bring to market solutions that will support doctors in assessing neurological diseases in innovative ways."
 
Frontier IP Chief Executive Officer Neil Crabb said: "We are delighted inSignals has been able to attract this investment from one of the major venture capitalists in Portugal. It provides a strong endorsement of the company and the potential of its technology, which is already attracting interest from leading neurologists across Europe."
 
ENQUIRIES
 



Frontier IP Group Plc


T: 020 7332 2338




Neil Crabb, Chief Executive
Andrew Johnson, Communications & Investor Relations
Company website: www.frontierip.co.uk


neil@frontierip.co.uk
M: 07464 546 025




Allenby Capital Limited (Nominated Adviser)


T: 0203 328 5656 




Nick Athanas / George Payne
 


 



ABout frontier IP 
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of hands-on commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology is validated and meets real world demands and needs. 
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT INESC TEC
INESC TEC is a research institution with 35 years of experience in R&D and technology transfer in Computer Science, Industrial and Systems Engineering, Networked Intelligent Systems, and Power and Energy. With 350 doctorates among 700 researchers, INESC TEC aggregates 13 centres with complementary competences that are focused on the international market and has a patent portfolio of 23 patent families in ICT and medical technologies.
 
The institution drives the research results to their valorisation and adoption through technology transfer processes, from licensing to collaborative development, advanced consulting and training or spin-off launching. 
 
ABOUT PorTugal Ventures
Portugal Ventures, a venture capital firm that is part of the Banco Português de Fomento group, currently manages 182 million euros and has more than 100 portfolio companies. It invests in startups in the pre-seed, seed and series A stages that offer innovative solutions for the international market in the digital, engineering & industry, life sciences, and tourism sectors. Since 2012, Portugal Ventures has invested 155 million euros in 147 new businesses. Learn more at www.portugalventures.pt.   
 
ABOUT REACH ANNOUNCEMENTS 
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.   Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
 
 
 
 
 
 
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAKZGMFKGGGMZM